Factive is a drug owned by Lg Chem Ltd. It is protected by 9 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 21, 2019. Details of Factive's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6331550 | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(5 years ago) |
Expired
|
| US6455540 | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(5 years ago) |
Expired
|
| US6262071 | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
Sep, 2019
(5 years ago) |
Expired
|
| US6803376 | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
Sep, 2019
(5 years ago) |
Expired
|
| US6340689 | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
Sep, 2019
(5 years ago) |
Expired
|
| US6723734 | Salt of naphthyridine carboxylic acid derivative |
Mar, 2018
(6 years ago) |
Expired
|
| US5776944 | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Apr, 2017
(7 years ago) |
Expired
|
| US5962468 | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Jun, 2015
(9 years ago) |
Expired
|
| US5633262 | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
Jun, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Factive's patents.
Latest Legal Activities on Factive's Patents
Given below is the list of recent legal activities going on the following patents of Factive.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 20 Apr, 2004 | US6723734 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Apr, 2004 | US6723734 |
| Issue Notification Mailed Critical | 01 Apr, 2004 | US6723734 |
| Receipt into Pubs | 22 Mar, 2004 | US6723734 |
| Application Is Considered Ready for Issue Critical | 18 Mar, 2004 | US6723734 |
| Receipt into Pubs | 16 Mar, 2004 | US6723734 |
| Mail Response to 312 Amendment (PTO-271) Critical | 12 Mar, 2004 | US6723734 |
| Response to Amendment under Rule 312 Critical | 12 Mar, 2004 | US6723734 |
| Issue Fee Payment Verified Critical | 16 Jan, 2004 | US6723734 |
| Issue Fee Payment Received Critical | 16 Jan, 2004 | US6723734 |
US patents provide insights into the exclusivity only within the United States, but Factive is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Factive's family patents as well as insights into ongoing legal events on those patents.
Factive's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Factive's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 21, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Factive Generic API suppliers:
Gemifloxacin Mesylate is the generic name for the brand Factive. 1 company has already filed for the generic of Factive. Check out the entire list of companies who have already received approval for Factive's generic
How can I launch a generic of Factive before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Factive's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Factive's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Factive -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 320 mg | 04 Mar, 2008 | 1 | 15 Jun, 2015 | 21 Sep, 2019 | Eligible |
Alternative Brands for Factive
Factive which is used for treating various bacterial infections., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Cumberland |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi Inc |
| |||||
| Wyeth Pharms |
| |||||
| Xellia Pharms Aps |
| |||||
About Factive
Factive is a drug owned by Lg Chem Ltd. It is used for treating various bacterial infections. Factive uses Gemifloxacin Mesylate as an active ingredient. Factive was launched by Lg Chem Ltd in 2003.
Approval Date:
Factive was approved by FDA for market use on 04 April, 2003.
Active Ingredient:
Factive uses Gemifloxacin Mesylate as the active ingredient. Check out other Drugs and Companies using Gemifloxacin Mesylate ingredient
Treatment:
Factive is used for treating various bacterial infections.
Dosage:
Factive is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 320MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |